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Abstract
Pharmaceuticals are continuously discarded into the aquatic system through wastewater treatment plants (WWTPs). The microbial degradation of these
organic micropollutants and formation of transformation products (TPs) under aerobic conditions is the fundamental process for their elimination. It is of
paramount importance to understand the microbial metabolic pathways so as to obtain knowledge of how fast micropollutants degraded and to assess the
exposure to their potential TPs as they can be more polar and consequently environmentally persistent.
In this study, batch reactors seeded with activated sludge from the WWTP of Athens were set up to assess biotic, abiotic and sorption losses of selective
psychotropic drugs, containing amine moieties. Biodegradation and transformation products were identified using liquid chromatography quadrupole-time-of-
flight mass spectrometry (LC-QToF-MS). A workflow for target, suspect and non-target screening was developed. Data treatment was performed by using
metabolite tools accompanying Bruker’s maxis impact ESI-QToF-MS and the structure elucidation of the candidate transformation products was based on
accurate mass and isotopic pattern measurements by HRMS and tentative interpretation of MS/MS spectra. Finally four biotransformation products were
identified for both lidocaine and ephedrine. Despite the structure similarities, different degradation constants were calculated for each compound.
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Amber bottles seeded with activated sludge under aerobic  
conditions in room temperature, pH≈7. 
Spiked samples with 1000 and 400 μg/L lidocaine and 
ephedrine, respectively. 
Two control samples for abiotic and sorption losses. One 
blank sample.
Incubation time: 24 hours for ephedrine and 12 days for 
lidocaine. 
Filtration through glass fiber syringe and then through 0.2
μm RC filter. 
UltiMate 3000™ RSLC (Dionex) UHPLC System
Column: Thermo Acclaim RSLC C18, 2.2 μm 120 
Å, 2.1x100 mm
Mobile Phase: +ESI→ MeOH:H2O (90:10)/H2O, 5 mM
Amm. formate & 0.01% Formic acid. -ESI → 
MeOH:H2O (90:10)/H2O, 5 mM Ammonium acetate. 
Flow rate: 200-480 μL/min
Inj. Volume: 5 μL
MS Mode: broad-band collision induced dissociation   
bbCID, (MS & MS/MS simultaneously)
Kinetic experiment: Parent compound (PC) removal 
and determination of t1/2 and Kobs.
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HR-MS & MS/MS data in a single run with resolution ≥30,000.
In a single workflow target, suspect and non-target screening was performed for the identification
and structure elucidation of biotransformation products.
Bruker’s Metabolomic tools allow metabolites to be rapidly identified.
Three TPs and one TP were found for lidocaine and ephedrine, respectively.
Fig 1. Structures of lidocaine and
ephedrine. Lidocaine is an amide with a
tertiary nitrogen and ethyl moieties.
Ephedrine is a secondary amine with
methyl moieties and a neighbor hydroxyl
group.
Determination of TPs with no prior knowledge.
Subtraction of the background (blank sample) with
Bruker’s MetaboliteDetect 2.0.
Generation of a peak list of unknown.
All the time interval samples were checked for
identification of a time trend and absence in
the blank.
Blank Sample
Background 
Subtraction
Sample 
Generation of peak list
Parameters
Ratio: 5, Δtime: 0.1
min, Δmass: 0.05 m/z
Mass Spectrum Parameters
Intensity threshold: 30%
Max. No. Peaks: 10
Afterwards, the detected m/z which
showed a time-trend, were treated
and annotated as potential TPs only
in case that the aforementioned
criteria were met.
Conclusions
C3H8N
(-0.5ppm, 3 mSigma)
C12H18N2O
(1.3 ppm, 2.3 mSigma)
MS Spectra
MS/MS Spectra
Determination of transformation products (TPs): In-
house databases were compiled for both PCs from
literature and prediction models (UM-PPS &
Metabolite Predict). The characterization of a
compound as TP was based on the following
criteria.
Criteria
• deltaRT ≤ 0.05 min
• Accuracy: Error ≤ 5 
ppm
• Isotopic fit: ≤ 20 
mSigma
• Intensity > 1000 
(+ESI) / 500 (-ESI)
• Occurrence of a 
time trend
207.1489 m/z
Matched peaks from both MS 
& MS/MS spectra send to 
MetFrag to identify probable 
structures
Consider Rt & common 
fragments with the PC
The fragment 58.0650 m/z is common in the MS/MS spectra for both lidocaine and
its metabolite.
b. Monoethylglycinexylidide
(MEGX) c. 3-OH Lidocaine
a. Ephedrone
(Methacathinone)
d. C13H18N2O
0.4 ppm
8.7 mSigma
Fig 2. Identified 
metabolites of 
ephedrine (a) and 
lidocaine (b,c and d).
